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Abstract
Aim: The study objectives were to investigate the association between selected CYP2C9 and 
VKORC1 single nucleotide polymorphisms with serious bleeding or thrombotic risk, and to 
estimate mean daily maintenance dose of warfarin and international normalized ratio 
measurements among Blacks receiving warfarin anticoagulation.
Methods: We conducted a retrospective cohort study among 230 Black adults receiving warfarin 
for a minimum of three consecutive months with a confirmed date of first dosage.
Results: A lower mean daily maintenance dosage of warfarin was required to maintain an 
international normalized ratio measurement within the therapeutic range among Blacks with the 
VKORC1-1639G>A variant alleles ([G/A vs G/G, p = 0.02], [A/A vs G/A, p = 0.008] and [A/A vs 
G/G, p = 0.001]).
Conclusion: Data indicated that VKORC1-1639A variant allele influenced warfarin daily 
maintenance dosage among our small, likely admixed Black patient population.
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Background
Since its approval for medical use in humans in 1954, warfarin – a vitamin K antagonist 
(VKA) – has been one of the most commonly prescribed drugs in history [1]. It is the most 
widely used oral anticoagulant worldwide to prevent and treat arterial and venous 
thromboembolism disorders. Main advantages of warfarin [2] are oral administration, high 
efficacy, low cost, monitoring of prothrombin time by international normalized ratio (INR) 
measurement and prevention of thromboembolism in valvular atrial fibrillation [3]. 
Warfarin, however, has considerable disadvantages, including a narrow therapeutic index, 
large inter-patient variability in dose–response relationship which requires frequent 
monitoring of prothrombin time by INR measurement, frequent dosage adjustments to avoid 
over-anticoagulation complicated by severe or life-threatening bleeding or under-
anticoagulation complicated by thromboembolic events, and interactions with food and over-
the-counter vitamins and herbs containing vitamin K – the natural antidote to warfarin [2,4–
5]. Because warfarin anticoagulation is associated with a high rate and severity of 
complications, it has been listed among the 10 drugs with the largest number of adverse 
events requiring treatment in hospital emergency departments [6].
It is well established that the pharmacokinetics of warfarin are influenced by the cytochrome 
P450–2C9 complex (CYP2C9) [7–12]. Results from early studies revealed that single 
nucleotide polymorphisms (SNPs) in CYP2C9 are associated with low warfarin dosage 
requirements in vivo [7] and in clinical studies [8]. Patients who were homozygous for 
CYP2C9*1 allele metabolized warfarin normally, whereas patients with the CYP2C9*2 and 
CYP2C9*3 polymorphisms had a reduced enzymatic activity and, consequently, a reduced 
S-warfarin metabolism and inactive metabolites, over-anticoagulation and an increased risk 
of bleeding complications [8]. In a retrospective cohort study conducted among Whites [9], 
patients with CYP2C9*2 and CYP2C9*3 alleles experienced bleeding episodes more 
commonly, and required a lower maintenance dosage and a longer time to achieve stable 
dosing compared with homozygous patients for CYP2C9*1.
Subsequent to the identification of VKORC1 [13,14], the gene coding for the enzyme 
targeted by coumarin derivatives, several polymorphisms in this gene – such as 1639G>A, 
1173C>T, 1542G>C, 3730G>A, 6853G>C and 7566C>T – were shown to influence the 
pharmacodynamic effects of warfarin on INR and, consequently, to be associated with inter-
individual variation in warfarin dosage requirements among White–American, African– 
American and Asian–American patients [15–17]. High dose (group A) and low-dose (group 
B) haplotypes (haplotype tag SNPs) – haplotypes H1, and H2 (group A) versus H7, H8 and 
H9 (group B) – have also been identified among patients receiving long-term warfarin 
maintenance therapy by screening 10 common noncoding VKORC1 SNPs [17]. Findings 
from several investigations indicated that VKORC1-1639G>A is an important determinant 
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for the variability in warfarin dosage requirements among African Americans [11,18–20], as 
well as among Whites, Blacks (predominantly African–Americans) and Asians from 11 
countries and four continents participating in the International Warfarin Pharmacogenetics 
Consortium (IWPC) [21]. In the IWPC study, VKORC1-1639G>A was associated with 
reduced warfarin dose requirements across the three ethnic groups studied. The inter-
individual dose variation explained by VKORC1-1639G>A, however, was much lower in 
Blacks than in Whites, and was largely accounted for the lower allele frequency in Blacks 
compared with Whites.
One goal of warfarin dosing is to understand the role that pharmacogenetics plays in 
individualized therapy, particularly in dosage requirements and risk of complications [22–
24]. Although numerous studies have been published describing the association between 
complications of warfarin therapy and CYP2C9 or VKORC1 polymorphisms among Whites, 
only a limited number of studies assessing these associations have been conducted among 
Blacks, populations characterized by a great genetic diversity [20] and by a high risk of 
thromboembolism and its complications [25]. There is evidence that genetic variations play 
a major role in the difference of warfarin dosage requirements not only between ethnic 
groups, but also within ethnic groups, such as the Black populations [20,26]. To investigate 
selected genetic factors that could influence the therapeutic maintenance dose of warfarin in 
Blacks, we conducted the Grady Coumadin Study, a small retrospective cohort study. We 
used a re-sequencing strategy to identify additional novel VKORC1 SNPs in regions that 
might be implicated in the variability in warfarin dosage and that might explain in part the 
genetic variations among our Black population. Our objectives were to investigate the 
associations between selected CYP2C9 and VKORC1 polymorphisms and the risk of 
serious or life-threatening bleeding or thrombotic events among Black patients on warfarin 
therapy during a 1-year maintenance phase, and to estimate warfarin maintenance dose 
requirements and INR measurements among these patients within their 1 year of follow-up.
Methods
Study design & subject enrollment
The Grady Coumadin Study was a retrospective pilot cohort study carried out at the 
Coumadin Clinic of Grady Memorial Hospital, a large public hospital affiliated with Emory 
Healthcare, in Atlanta, GA, USA, between February 2005 and October 2006. The study 
protocol was approved by the Institutional Review Boards at the two participating 
institutions – Emory University School of Medicine and the Centers for Disease Control and 
Prevention (CDC). Eligibility criteria comprised: patients being on warfarin therapy for at 
least three consecutive months, having a confirmed date of first warfarin dosage, and 
patients being 18 years of age or older. These criteria encompassed patients with 
thromboembolic disease, myocardial infarction, atrial fibrillation and prosthetic heart valves. 
The exclusion criteria comprised: an inability to document the initial dose, an inability to 
collect a blood sample and documentation of repeated noncompliance with warfarin therapy 
by staff data collection. There was no restriction based on sex or race. Patients were enrolled 
in the study after informed consent was obtained; 245 patients were eligible to participate (n 
= 230 Blacks, n = 13 Whites and n = 2 of unknown race).
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Data collection & study end points
Data were collected by a clinic nurse and a cardiology fellow and consisted of a review of 
inpatient and outpatient medical records. Information on the INR measurements and 
warfarin dosing was obtained for each study participant. The target range for INR was 2.0–
3.0 except for patients with prosthetic heart valves whose range was 2.5–3.5. Medical 
information abstracted from chart review was kept in a secured location in a locked file 
cabinet. A 5-ml sample of blood was drawn for DNA testing. Serious or life-threatening 
bleeding complications were defined as a drop in hematocrit (>35%) that was associated 
with clinical bleeding and the need for blood transfusion. Thrombotic complications were 
obtained by chart review and comprised embolic stroke, pulmonary embolism, deep vein 
thrombosis and other systemic embolism. Other variables collected from chart review that 
are known to influence warfarin dosage were race, sex, age at enrollment, indications for 
warfarin therapy (atrial fibrillation or flutter; congestive heart failure; cerebrovascular 
accident; deep vein thrombosis or pulmonary embolism, or both; left ventricular thrombus; 
and heart valve replacement or repair), co-morbid conditions (arrhythmia, congestive heart 
failure, diabetes mellitus, hypertension and protein C or S deficiency), vitamin or herbal 
supplement intake and current smoking status [2,4,27].
Sample collection
Every attempt was made to collect the blood samples at the time of a routine blood draw, 
and samples were stored at 4°C until shipped via a courier to the CDC. DNA was extracted 
according to the manufacturer’s protocol using the PureGene DNA extraction kit (MN, 
USA) and stored at the CDC. The DNA was tested only for variables related to bleeding and 
clotting disorders.
Candidate SNP selection
For the CYP2C9 and VKORC1 genes, variants that result in a coding nonsynonymous 
amino acid substitution or have been previously reported to alter warfarin pharmacokinetics 
were selected for genotyping. Additionally, a re-sequencing strategy was employed to 
characterize additional genetic variation in this Black patient population. For SNP discovery, 
sequencing of the VKORC1 exons and 5’ region were performed on a subset of study 
samples (n = 125). Primers for sequencing each of the VKORC1 exons and 5’ region were 
designed in the laboratory and synthesized in the CDC core facility. DNA sequencing was 
performed on a 3730 DNA analyzer (Applied BioSystems, CA, USA), and results were 
analyzed using Sequencing Analysis 5.2 software (Applied Biosystems).
Genotyping
Selected CYP2C9 and VKORC1 SNPs were genotyped with TaqMan ® Drug Metabolism 
genotyping assays according to manufacturer protocols (Applied Biosystems). Amplification 
was carried out in 25 μl in a GeneAmp PCR System 9700 (Applied BioSystems), and 
fluorescence signals from samples and no-template controls were analyzed on a 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Genotypes were determined by manual 
review of each allelic discrimination plot with Sequence Detection System Version 2.3 
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software (Applied Biosystems). At least 10% of the samples were repeated and confirmed. 
All genotyping assay SNP results were validated by comparison with re-sequencing results.
We genotyped four CYP2C9 polymorphisms – CYP2C9*2 430C>T (coding variant; R144C; 
rs1799853), CYP2C9*3 1075A>C (coding variant; I359L; rs1057910), CYP2C9*5 
1080C>G (coding variant; D360E; rs28371686) and CYP2C9*6 187delA (coding variant; 
K273Rfs; rs9332131) [28] – and 16 VKORC1 polymorphisms – VKORC1-1639G>A 
(upstream-variant-2KB; rs9923231), VKORC1 4633A>G (upstream-variant-2KB; 
rs184617062), VKORC1 4719T>C (intron-variant; rs17878259), VKORC1 4835G>A 
(upstream-variant-2KB; rs17883590), VKORC1 5373T>C (coding variant exon 1; novel), 
VKORC1 5387G>A (coding variant exon 1; novel), VKORC1 5396G>A (coding variant 
exon 1; Val29Leu; rs104894539), VKORC1 5417G>T(coding variant exon 1; Asp36Tyr; 
rs61742245), VKORC1 5445T>A (coding variant exon 1; Val45Ala; rs104894540), 
VKORC1 6642G>A (coding variant exon 2; Val66Met; rs72547529), VKORC1 6746C>T 
(intronic variant; novel), VKORC1 6763C>G (intronic variant; rs200039618), VKORC1 
6853G>C (intronic variant; rs8050894), VKORC1 6915C>T (intronic variant; rs17886199), 
VKORC1 8773C>T (coding variant exon 3; Leu120Leu; rs7200749) and VKORC1 
8798T>G (coding variant exon 3; Leu128Arg; rs104894542) [29]. Upstream-variant 2KB is 
defined as a sequence variant located within 2KB 5’ of a gene [28,29].
Statistical methods
Primary end points were: serious or life-threatening bleeding complications, thrombotic 
complications, daily maintenance warfarin dosage (in mg) and INR at 6-month and 1-year 
follow-up. We calculated the minor allele frequency (MAF) – the frequency of the less 
common allele – for each of the CYP2C9 and VKORC1 polymorphisms, and grouped the 
MAFs into four categories: common alleles (MAF >5%), rare alleles (2% ≤ MAF ≤ 5%), 
very rare alleles (0% < MAF ≤ 1%) and alleles without variation (MAF = 0%). We = 
compared the distribution of selected demographic and clinical characteristics of each of the 
CYP2C9 and the VKORC1 variant alleles with their respective reference allele using chi-
square test or Fisher’s exact test, and calculated the risk ratios and 95% confidence intervals. 
Specifically, for the four CYP2C9 genotypes, the reference alleles were, respectively, 
CYP2C9*2 430C/C, CYP2C9*3 1075A/A, CYP2C9*5 1080C/C, CYP2C9*6 817A/A. For 
the 16 VKORC1 genotypes, the reference alleles were, respectively, VKORC1-1639G/G, 
VKORC1 4633A/A, VKORC1 4719T/T, VKORC1 4835G/G, VKORC1 5373T/T, VKORC1 
5387G/G, VKORC1 5396G/G, VKORC1 5417G/G, VKORC1 5445T/T, VKORC1 
6642G/G, VKORC1 6746C/C, VKORC1 6763C/C, VKORC1 6853G/G, VKORC1 
6915C/C, VKORC1 8773C/C, VKORC1 8798T/T.
We compared the prescribed daily maintenance dosage of warfarin as well as the INR at 6-
month and 1-year follow-up between the different alleles for each of the CYP2C9 and 
VKORC1 SNP within our group of patients using a nonparametric analysis based on the 
Wilcoxon-Mann–Whitney test (or Wilcoxon-rank-sum test), with a level of statistical 
significance at 0.05. We also analyzed variant allele data following the logarithmic 
transformation of the warfarin mean doses, and performed linear regression analysis to 
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assess the association between each genotype with the logarithmic transformed means of 
warfarin maintenance doses.
All statistical analyses were performed using SAS 9.3 (SAS Institute, Inc, NC, USA).
Results
We restricted our analyses to Black participants (n = 230). Among the 230 Black 
participants, 29 patients (12.6%) were lost to follow-up during the 1-year follow-up period 
and, among those, six were lost before 6-month follow-up.
Allelic frequencies of the four CYP2C9 polymorphisms and the 16 VKORC1 
polymorphisms among our Black population are summarized in Supplementary Table 1. We 
included in analyses the four polymorphisms with common alleles – VKORC1-1639G>A, 
VKORC1 6853G>C, VKORC1 6915C>T and VKORC1 8773C>T – and the two 
polymorphisms with rare alleles – CYP2C9*2 and VKORC1 4719T>C. Because of the very 
small sample sizes, we excluded the six polymorphisms with very rare alleles – CYP2C9*3, 
CYP2C9*5, CYP2C9*6, VKORC1 4835G>A, VKORC1 6642G>A, VKORC1 6763C>G – 
as well as the eight polymorphisms showing little or no variation among our population – 
VKORC1 4633A>G, VKORC1 5373T>C VKORC1 5387G>A, VKORC1 5396G>A, 
VKORC1 5417G>T, VKORC1 5445T>A, VKORC1 6746C>T, VKORC1 8798T>G.
Table 1 presents the distribution of demographic and clinical characteristics by CYP2C9*2, 
VKORC1 4719T>C and VKORC1-1639 polymorphisms. The distribution of atrial 
fibrillation or atrial flutter was higher among Blacks with VKORC1 4719 variant alleles 
compared with Blacks with the reference allele (Fisher’s exact test, p = 0.0009). We did not 
observe a significant difference in the occurrences of bleeding or thrombotic complications 
or in the distributions of demographic characteristics and co-morbid conditions among 
Blacks with CYP2C9*2 or VKORC1 4719 variant alleles when compared with those with 
their respective reference allele (data not shown). None of the Black patients with 
CYP2C9*2 or VKORC1 4719 genotype had antithrombin III deficiency, homocysteinemia 
or peripheral vascular disease.
Among Blacks with the variant alleles for VKORC1-1639 (Table 1), VKORC1 6853, 
VKORC1 6915 or VKORC1 8773 (data not shown), we did not observe a significant 
difference in the occurrences of bleeding or thrombotic complications, or a significant 
difference in the distributions of warfarin indications and co-morbid conditions compared 
with Blacks with the reference alleles within our group of patients (data not shown). None of 
the Black patients with VKORC1-1639, VKORC1 6853, VKORC1 6915 or VKORC1 8773 
polymorphisms had antithrombin III deficiency, homocysteinemia or peripheral vascular 
disease.
As shown in Table 2, the mean daily maintenance dosage of warfarin required to maintain an 
INR measurement within the therapeutic range was not statistically different among Black 
study patients who were heterozygous for CYP2C9*2 or VKORC1 4719T>C 
polymorphisms compared with those with their respective reference allele. A lower mean 
daily dosage of warfarin was required to maintain an INR measurement within the 
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therapeutic range among Blacks who were homozygotes or heterozygotes for 
VKORC1-1639 and VKORC1 6853 polymorphisms, and the difference in mean daily 
dosages of warfarin for these polymorphisms was statistically significant. When we 
considered the logarithm of warfarin mean daily maintenance dosages as the dependent 
variable in univariate linear regression models, we found a statistically significant 
association with VKORC1-1639 (p = 0.001) and with VKORC1 6853 (p = 0.027). For the 
VKORC1-1639 polymorphism, the warfarin maintenance genetic polymorphism for 
VKORC1 6853. Our data analysis indicated that VKORC1–1639 and VKORC1 6853 were 
correlated in a linear regression model, and were in linkage disequilibrium (LD; squared 
allele-frequency correlation [r2] = 0.41). When VKORC1-1639 and VKORC1 6853 
polymorphisms were concomitantly included as independent variables for the logarithm of 
mean warfarin dosage in a multivariate linear regression model, only VKORC1-1639 
remained statistically significant (p = 0.036).
Discussion
This cohort study revealed that a lower mean daily maintenance dosage of warfarin was 
required to maintain an INR measurement within the therapeutic range among Blacks with 
VKORC1-1639G>A (rs9923231), and the dose effect of genetic polymorphism followed a 
negative linear trend with homozygous patients VKORC1-1639 A/A requiring the lowest 
dosage. We also found a statistically significant association between atrial fibrillation or 
atrial flutter and the rare SNP VKORC1 4719T>C (rs17878259). In our small, likely 
admixed Black patient population, many of the other polymorphisms were very rare or 
completely monomorphic showing no variation. We did not observe a significant difference 
in the occurrences of bleeding or thrombotic complications among Blacks with 
VKORC1-1639G>A (rs9923231), 6853G>C (rs8050894), 6915T>C (rs17886199), 
8773C>T (rs7200749) polymorphisms (MAF >5%), and VKORC1 4719T>C (rs17878259) 
and CYP2C9*2 (rs1799853) polymorphisms (2% ≤ MAF ≤ 5%), when compared with those 
with their respective reference alleles.
The genetic variability for the CYP2C9 and VKORC1 genotypes across ethnic groups varied 
among studies [21,30–32]. Our findings agreed with those of previous studies that 
VKORC1-1639G>A is a major predictor of warfarin maintenance dosage among Blacks, 
and patients with G/A or A/A variant alleles necessitated a lower warfarin dosage than those 
with G/G variant alleles [10–11,18–19,21]. Also in agreement with other investigations 
among African–Americans [33,34], the VKORC1 6853G>C polymorphism was not a 
predictor of warfarin dosage requirement, although Limdi et al.’s study [34] revealed that 
VKORC1-1639 and VKORC1 6853 were both predictive of warfarin dosage requirement 
among White–Americans. In contrast to other studies focusing on VKORC1 8773 among 
White–Canadians [35], or on VKORC1 6915 among African–Americans [36], we did not 
find that VKORC1 8773 or VKORC1 6915 polymorphisms were associated with a lower 
warfarin dosage requirement in our Black population, likely because of the small sample 
size of the population. Furthermore, previous research investigations showed strong evidence 
that promoter and intronic variants VKORC1-1639G>A and VKORC1 6853G>C (as well as 
1173C>T and 7566C>T) were in complete LD [16], and were both present in VKORC1*2 
haplotype (H2) [16,37]. Our data analysis indicated that VKORC1-1639 and VKORC1 6853 
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were in LD ([r2] 0.41), confirming Geisen’s finding [16]. Further adjustment for each 
genotype versus the other genotype led us to conclude that VKORC1-1639G>A was the 
important genetic factor associated with warfarin sensitivity among our Black study 
participants.
Because CYP2C9*2, CYP2C9*3 and VKORC1-1639G>A variant alleles are less frequent in 
Blacks and can only partly explain their warfarin dose variability, further investigations were 
carried out to identify additional variant alleles that could alter the response to warfarin 
therapy in Black populations. For example, studies in multiethnic groups showed that 
CYP2C9*5, *6, *8 and *11 variants were found in higher frequency in Blacks than in 
Whites. Specifically, these alleles influenced the variability in warfarin maintenance dosage 
among African–Americans and were associated with decreased function of the CYP2C9 
enzyme [10–12,38]. In indigenous African populations, a reduction of warfarin dose 
requirements was also observed with the CYP2C9*8 polymorphisms in Black populations 
from South Africa [39], and with the CYP2C9*5, *6 and *11 polymorphisms in patients 
from Sudan [40]. In our study, however, CYP2C9*5 and CYP2C9*6 variants were excluded 
from the analysis because of very low allelic frequencies, and CYP2C9*8 and CYP2C9*11 
variants were not studied.
Frequency distributions of minor alleles for CYP2C9 and VKORC1 polymorphisms vary 
across ethnically diverse populations [15–16,21,41]. In our study, genotype frequencies for 
CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, VKORC1-1639G>A, VKORC1 
6853G>C, VKORC1 6915C>T and VKORC1 8773C>T among our Black population were 
in line with those from several investigations in African–Americans [10–11,18–21,32–
34,38,40–44] and various public resources [16,45–47]. Furthermore, frequencies of minor 
alleles for CYP2C9*5, CYP2C9*6, VKORC1 6853G>C and VKORC1 8773G>A 
polymorphisms in our Black population were similar to those among indigenous African 
populations, such as Black populations from South Africa [39], Benin [48], Mozambique or 
Angola [49]. Allelic frequencies for CYP2C9*2, CYP2C9*3 and VKORC1-1639G>A in our 
study of Black population, however, slightly differed from those reported in several studies 
conducted among Sub-Saharan African populations. For example, CYP2C9*2 and 
CYP2C9*3 variant alleles were not detected in any of genotyped study participants 
consistent with Black–Africans from Ghana [50,51], Benin [48,52], Mozambique [53] or 
South Africa [39,54], whereas, in our study, we detected 2 and 1% frequencies of minor 
alleles for CYP2C9*2, CYP2C9*3, respectively, among our Black participants. In addition, 
VKORC1-1639G>A allelic frequencies were lower in populations from Mozambique or 
Angola [49] (3.5 and 2.7%, respectively) compared with those in our Black population 
(13%).
Several novel genotypes shown to significantly improve warfarin dose prediction were 
identified in studies conducted among Black populations. The gene caluminium (CALU) – a 
variant in a VKORC1 regulator – was shown to influence warfarin requirements [38,55]. In 
particular, CALU rs339097 A>G was associated with higher warfarin dose requirements in 
African–Americans [55]. The gamma-glutamyl carboxylase (GGCX [rs10654848]) gene 
was also identified in African–Americans and was significantly associated with higher 
warfarin stable dose requirements [36,38,43]. In the first genome-wide association study 
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focusing on genetic influence of warfarin dose requirements which included Blacks, 
investigators identified rs12777823 variant in the CYP2C cluster near the CYP2C18 gene on 
chromosome 10 among their Black study participants [44]. They conducted an initial 
genome-wide association study followed by replication cohort studies, and found that Black 
participants (mainly originating from West Africa) with rs12777823 variant needed a 
warfarin dose reduction. Because this variant was not associated with warfarin dose 
requirements in Whites or in Asians, it was suggested that the rs12777823 variant was not 
causal but in LD with one or more rare causal variants in Blacks [56]. Nevertheless, the 
association between rs12777823 genotype and warfarin dose reduction was subsequently 
confirmed in further studies [57]. In a study on extreme warfarin doses with African–
American participants, investigators found evidence that a population-specific regulatory 
variant in the folate homeostasis gene folylpolyglutamate synthase (FPGS [rs7856096]) 
might influence warfarin dose [58]. On the other hand, several other genes have been 
identified such as EPHX1, APOE or CYP4F2, and have been shown to influence warfarin 
dose requirements in Whites, but not, or inconsistently, in African-descent populations 
(findings from these studies are summarized in Suarez-Kurtz and Botton’s comprehensive 
literature review [59]). In our study, we did not investigate the association between CALU 
rs339097, GGCX rs10654848, CYP2C rs12777823 or FPGS rs7856096 variants and 
warfarin dose variability among our Black population because our study was conducted 
before these SNPs were identified.
The difference in warfarin maintenance dosage requirement between ethnic groups has been 
attributed to genetic factors as well as to clinical and environmental factors. Numerous 
dosing algorithms for warfarin have been derived from multiple regression models to predict 
the stable therapeutic dosage of warfarin. For example, investigators from the IWPC derived 
dosing algorithms using data from geographically diverse patients, and included clinical 
factors (warfarin indication, target INR and interacting drugs), demographic variables (age, 
race, weight and height) and genetic variables (CYP2C9 and VKORC1 genotypes) [21,23]. 
They concluded that incorporating genotype information improved clinical outcomes, 
especially for patients who required much higher or lower warfarin dosages. A meta-analysis 
of randomized controlled trials comparing genotype-guided with standard-VKA (such as 
warfarin) dosing algorithms in adults initiating anticoagulation, however, did not find a 
decrease of a composite outcome of death, major bleeding and thromboembolic events [60]. 
They did observe an improvement in time in therapeutic range when they compared 
genotype-guided with fixed-VKA dosing algorithms, but not with clinical algorithms [60].
Since 2007, the US FDA mandated that information about CYP2C9 and VKORC1 variants 
be included in the labeling information of warfarin [22,61]. In 2010, the FDA updated the 
label to include dosing recommendations on CYP2C9 and VKORC1 genotypes [62]. 
CYP2C9*2, CYP2C9*3 and VKORC1-1639G>A variants are included in the FDA table to 
guide warfarin dosing [63], as well as in the IWPC algorithm [23]. Although these 
polymorphisms accounted for more than 40% of the variability in warfarin dose in Whites, 
they explained only 20% of the variability in warfarin dose in Black populations [21–23]. 
Therefore, advances in pharmacogenetics-based warfarin therapy providing clinicians with a 
personalized approach to estimate the initial therapeutic dose of warfarin therapy when 
genotype information is available [63] benefit predominantly White populations. There is a 
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major limitation of current standard practice of genetic testing in clinical medical care 
associated with warfarin therapy since it is mainly applicable to the White patient 
populations from Europe or the USA. More research is needed in the Black populations to 
assist in the development of pharmacogenetics-based guidelines for warfarin dosing among 
populations of African ancestry.
Two large prospective clinical trials sponsored by the National Heart, Lung, and Blood 
Institute were conducted in the USA to examine warfarin pharmacogenetics – the 
Clarification of Optimal Anticoagulation Through Genetics (COAG) study and the Genetics 
Informatics Trial (GIFT) of Warfarin Therapy to Prevent Deep Venous Thrombosis study. 
Although the COAG clinical trial included an ethnically diverse population with 27% 
African Americans, it was limited to CYP2C9*2, CYP2C9*3 and VKORC1-1639 genetic 
variants. The COAG trial found no difference in pharmacogenetic dosing of warfarin 
compared with a clinical algorithm [64,65]. Because genetic variants specific to African–
Americans such as CYP2C9 (*5, *6, *8 and *11) variants, or rs12777823, were not included 
in the COAG trial, some authors suggested that the algorithm used in this trial over-
estimated warfarin dose in African–Americans who had CYP2C9 (*5, *6, *8 and *11) 
variants [66,67]. The GIFT clinical trial, on the other hand, quantified the benefit of 
pharmacogenetic dosing of warfarin on clinical events in orthopedic patients and included 
CYP2C9*2, CYP2C9*3, VKORC1-1639 and CYP4F2*3 genetic variants [68,69]. Results of 
the GIFT trial indicated that genotype-guided dosing was associated with a 27% reduction in 
the composite outcome of death, confirmed venous thromboembolism, warfarin overdose 
(INR ≥4) and major bleeding as compared with clinical algorithm dosing, and a statistically 
significant improvement in INR control among the study population. These results may be 
promising and could provide a good illustration of the importance of personalized medicine 
[69].
Our study had several strengths. First, it comprised a sample of Blacks, an ethnic group with 
wide, complex and heterogeneous genetic diversity for whom there is currently a knowledge 
gap related to warfarin pharmacogenetics. Second, we used a conservative case definition of 
a bleeding event and only patients who experienced major bleeding episodes were counted 
as bleeding events. By restricting bleeding events to those which were serious and life 
threatening, we created a more specific case definition with fewer false-positives. Because 
our case definition was not sensitive, we probably missed patients with mild or moderate 
bleeding episodes, and might have underestimated the risk of complications associated with 
CYP2C9 and VKORC1 variant alleles. Our study, however, has several limitations. First, 
bias from loss to follow-up or loss to competing risks might have occurred if censoring was 
related to the outcomes. Specifically, selection bias might have arisen if the 29 Black 
patients who withdrew from the cohort had different frequencies of bleeding or thrombotic 
events, or had different distributions of daily maintenance warfarin dosages according to 
CYP2C9 and VKORC1 variant alleles from those who remained in follow-up. Second, our 
study did not include information on the induction phase, and therefore, we were unable to 
estimate the time to stable dosing in relation to the genetic risk factors, in particular 
VKORC1 polymorphisms. Third, we had small numbers making some data unreliable. 
Fourth, we did not have information on medications, such as amiodarone, statins, to assess 
drug interactions with warfarin. The majority of the results are related to dose and dose 
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would be directly affected by drug interactions. Finally, our Black population is likely 
admixed. However, admixture had to remain unresolved in our study because we could not 
test or control for admixture in association testing. There is large genomic diversity in Africa 
and tests which are developed fail to take this variation into account might fall short of 
offering universal efficacious testing.
Conclusion
This pilot study consisting of a small, likely admixed patient population showed that 
VKORC1-1639G>A variant alleles were associated with a lower mean daily maintenance 
dosage of warfarin independently of the VKORC1 6853 polymorphism among Blacks 
receiving warfarin therapy. Because allele frequencies differ between ethnic groups, more 
studies are needed to detect novel genotypes among ethnically diverse populations receiving 
warfarin anticoagulation. Such studies might provide references for the development of 
dosing protocols designed to reduce the risk of complications associated with warfarin 
among different ethnically diverse populations.
Future research could include a cohort with a larger sample of Black participants from 
various ethnic groups of African ancestry to allow enrichment for rare alleles, as well as to 
adjust for censoring and potential confounding variables, and to detect gene–gene 
interactions and gene–environment interactions. Future research could also include clinical 
or epidemiologic studies designed to investigate whether CYP2C9 and VKORC1 
polymorphisms and other genotypes are more important genetic determinants of warfarin 
dosage among patients with bleeding disorders, such as hemophilia, compared with those 
without bleeding disorders.
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Executive summary
• Although numerous published studies described the association between 
complications of warfarin anticoagulation and CYP2C9 or VKORC1 single 
nucleotide polymorphisms (SNPs) among Whites, few studies assessing these 
associations have been performed among Blacks.
• In this retrospective cohort study of a small, likely admixed Black patient 
population receiving warfarin anticoagulation, we investigated whether four 
genotyped CYP2C9 SNPs and 16 VKORC1 SNPs identified by re-sequencing 
were associated with serious bleeding or thrombotic risk. We also estimated 
mean daily maintenance dosage of warfarin and international normalized ratio 
in this population.
• We conducted the Grady Coumadin Study, a small retrospective cohort study 
among 230 Blacks 18 years or older (comprising 124 men and 106 women) 
receiving warfarin for a minimum of three consecutive months with a 
confirmed date of first dosage from February 2005 through October 2006.
• A lower mean daily maintenance dose of warfarin was required to maintain an 
international normalized ratio measurement within the therapeutic range 
among Blacks with the VKORC1–1639G>A variant alleles ([G/A vs G/G, p = 
0.02], [A/A vs G/A, p = 0.008] and [A/A vs G/G, p = 0.001]) using 
Wilcoxon-Mann–Whitney test.
• The warfarin maintenance dose decreased with the increased number of 
variant alleles among Blacks with VKORC1–1639G>A, indicating a negative 
dose effect of genetic polymorphism (P trend test = 0.0008).
• Our data did not indicate a significant difference in the occurrences of 
bleeding or thrombotic complications among Blacks with VKORC1–
1639G>A, 6853G>C, 6915T>C, 8773C>T polymorphisms (MAF > 5%), and 
VKORC1 4719T>C and CYP2C9*2 430C>T polymorphisms (2% ≤ MAF ≤ 
5%).
• Because allele frequencies differ between ethnic groups, more studies are 
needed to detect novel CYP2C9 and VKORC1 polymorphisms and other 
genotypes among ethnically diverse populations, especially of African 
ancestry, receiving warfarin anticoagulation.
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Table 1.
Distribution of demographic and clinical characteristics by CYP2C9*2 430C>T, VKORC1 4719T>C and 
VKORC1-1639G>A single nucleotide polymorphisms among Blacks: The Grady Coumadin Study, Atlanta, 
Georgia, 2005–2006.
Variables CYP2C9*2 VKORC1 4719T>C VKORC1–1639G>A
Variant allele 
C/T
Reference allele 
T/T
Variant allele 
T/C
Reference allele 
T/T
Variant alleles 
G/A or A/A 
combined
Reference 
allele G/G
Demographics
Subjects, no. (%) 8 (4.2) 184 (95.8) 7 (3.2) 213 (96.8) 51 (24) 165 (76)
Male, no. (%) 4 (50.0) 100 (54.4) 4 (57.1) 120 (56.3) 31 (61) 88 (53)
Age, mean (SD; years) 57.4 (8.81) 58.5 (12.2) 61.4 (15.8) 58.5 (12.0) 59.2 (11.9) 58.5 (12.3)
6-month follow-up (days)
Mean 181 181 180 181 180.5 182
Median 182 183.5 188 183 182 185
Range 168–189 34–273 34–273 50–270 50–219 34–273
1-year follow-up (days)
Mean 369 358 347 360 357 361
Median 364 364 361 364 364 364
Range 361–392 258–406 266–385 258–406 262–384 258–406
Warfarin complications, 
no. (%)
Serious bleeding 2 (25.0) 15(8.2) 0 (0.0) 18 (8.5) 6(12) 13(8)
Thrombosis 0 (0.0) 7 (3.8) 0 (0.0) 8 (3.8) 1 (2) 6(4)
Indications for warfarin, 
no. (%)
Atrial fibrillation/atrial 
flutter 1 (12.5) 73 (39.7) 7 (100.0)† 76 (35.7) 21 (41) 60 (36)
Coronary arterial disease 0 (0.0) 1 (0.54) 0 (0.0) 1 (0.47) 0 (0.0) 1 (0.6)
Dilated cardiomyopathy/
congestive heart failure 0 (0.0) 15(8.2) 0 (0.0) 17 (8.0) 3 (6) 14 (8)
Cerebrovascular accident 2 (25.0) 18 (9.8) 0 (0.0) 26 (12.2) 9 (18) 16(10)
DVT/PE 4 (50.0) 56 (30.4) 0 (0.0) 69 (32.4) 12 (24) 56 (34)
Left ventricular thrombus 0 (0.0) 6 (3.3) 0 (0.0) 6(2.8) 2 (4) 5(3)
Pulmonary hypertension 0 (0.0) 2(1.1) 0 (0.0) 2 (0.94) 0 (0.0) 2(1)
Peripheral vascular disease 0 (0.0) 1 (0.54) 0 (0.0) 1 (0.47) 0 (0.0) 1 (0.6)
Valve replacement/repair 1 (12.5) 31 (16.9) 1 (14.3) 34 (16.0) 6(12) 28 (17)
Other 0 (0.0) 1 (0.54) 0 (0.0) 2 (0.94) 0 (0.0) 2(1)
Co-morbid conditions, 
no. (%)
Atrial fibrillation/atrial 
flutter 0 (0.0) 1 (0.54) 0 (0.0) 2 (0.94) 0 (0.0) 2(1)
Arrhythmia 1 (12.5) 21 (11.4) 0 (0.0) 24 (11.3) 7(14) 16(10)
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Variables CYP2C9*2 VKORC1 4719T>C VKORC1–1639G>A
Variant allele 
C/T
Reference allele 
T/T
Variant allele 
T/C
Reference allele 
T/T
Variant alleles 
G/A or A/A 
combined
Reference 
allele G/G
Cancer 0 (0.0) 14 (7.6) 0 (0.0) 17 (8.0) 6(12) 11 (7)
Congestive heart failure 3(37.5) 50 (27.2) 3 (42.9) 57 (26.8) 11 (22) 46 (28)
Cerebrovascular accident 0 (0.0) 8 (4.4) 0 (0.0) 8 (3.8) 3 (6) 5(3)
Diabetes mellitus 1 (12.5) 50 (27.2) 2 (28.6) 59 (27.7) 13(25) 47 (28)
Hypertension 7(87.5) 1 53 (83.2) 6 (85.7) 176 (82.6) 43 (84) 136 (82)
Valve replacement/repair 0 (0.0) 1 (0.54) 0 (0.0) 1 (0.47) 1 (2) 0 (0.0)
History of DVT/PE 0 (0.0) 4(2.2) 0 (0.0) 4 (1.9) 1 (2) 3(2)
Factor V Leiden 0 (0.0) 1 (0.54) 0 (0.0) 1 (0.47) 0 (0.0) 1 (0.6)
Protein C or S deficiency 0 (0.0) 3(1.6) 0 (0.0) 4 (1.9) 2 (4) 2(1)
Current smoker, no. (%) 2 (25.0) 59 (32.1) 1 (14.3) 68 (31.9) 20 (39) 49 (30)
Vitamin or herb intake, 
no. (%) 3(37.5) 46 (25.0) 1 (14.3) 54 (25.4) 12 (24) 40 (24)
†
Fisher exact test, p = 0.0009.
DVT: Deep vein thrombosis; PE: Pulmonary embolism; SD: Standard deviation; VK: VKORC1 genotype.
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Table 2.
Prescribed daily maintenance dose of warfarin and mean international normalized ratio in relation to CYP2C9 
and VKORC1 single nucleotide polymorphisms with minor allele frequency ≥ 2% among Blacks: The Grady 
Coumadin Study, Atlanta, Georgia, 2005–2006.
Single nucleotide 
polymorphism No.
Daily maintenance warfarin dose 
(mg) International normalized ratio
Mean (SD) Median (IQR) Mean (SD) at 
enrollment
Mean (SD) at 6 
months
Mean (SD) at 1 
year
CYP2C9*2
C/C 184 7.0 (4.5) 6.1 (4.6) 2.6 (1.1) 2.7 (1.5) 2.8 (1.5)
C/T 8 4.8 (1.6) 5.0 (2.0) 2.3 (0.58) 2.3 (0.61) 2.6 (0.93)
T/T 0 - - - - -
VKORC1 4719T>C
T/T 213 6.9 (4.5) 6.1 (4.5) 2.6 (1.1) 2.6 (1.4) 2.8 (1.4)
T/C 7 5.1 (2.0) 4.3 (3.9) 2.7 (0.71) 3.4 (1.7) 2.4 (0.38)
C/C 0 - - - - -
VKORC1–1639G> A
G/G 165 7.0 (3.8) 6.4 (3.9) 2.6 (1.1) 2.6 (1.6) 2.8 (1.5)
G/A 45 6.9 (6.5)† 5.0 (2.9) 2.5 (0.96) 2.7 (1.2) 2.6 (1.3)
A/A 6 2.9 (1.2)‡,§ 2.5 (1.1) 2.7 (1.0) 2.3 (0.87) 2.1 (0.49)
VKORC1 6853G>C
G/G 116 7.2 (4.0) 6.4 (3.9) 2.5 (1.1) 2.6 (1.3) 2.7 (1.2)
G/C 62 6.4 (4.5)¶ 5.0 (3.9) 2.7 (1.1) 2.5 (0.93) 2.8 (1.8)
C/C 29 6.5 (6.2)# 5.0 (4.4) 2.4 (0.79) 3.1 (2.3) 2.5 (1.0)
VKORC1 6915C>T
C/C 195 7.0 (4.7) 6.1 (4.6) 2.6 (1.1) 2.6 (1.5) 2.8 (1.4)
C/T 23 6.4 (2.2) 6.1 (2.6) 2.7 (1.1) 2.7 (1.2) 2.5 (1.2)
T/T 1 4.3 (0.0) 4.3 (0.0) 2.8 (0.0) 2.5 (0.0) 2.4 (0.0)
VKORC1 8773C>T
C/C 138 6.8 (4.7) 5.0 (3.6) 2.6 (1.0) 2.6 (1.6) 2.8 (1.4)
C/T 73 7.1 (4.2) 6.4 (5.0) 2.6 (1.1) 2.6 (1.2) 2.8 (1.6)
T/T 9 5.9 (2.9) 5.0 (4.1) 2.6 (1.3) 2.6 (0.97) 2.3 (0.81)
†Wilcoxon-Mann–Whitney test, p = 0.02 between G/A and G/G genotypes for VKORC1–1639G>A.
‡Wilcoxon-Mann–Whitney test, p = 0.001 between A/A and G/G genotypes for VKORC1–1639G>A.
§Wilcoxon-Mann–Whitney test, p = 0.008 between A/A and G/A genotypes for VKORC1–1639G>A.
¶Wilcoxon-Mann–Whitney test, p = 0.046 between G/C and G/G genotypes for VKORC1 6853G>C.
#Wilcoxon-Mann–Whitney test, p = 0.03 between C/C and G/G genotypes for VKORC1 6853G>C.
IQR: Interquartile range; SD: Standard deviation.
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